Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: Is that a latent disadvantage?

Figure 1

Fenofibrate showed no improvement in glucose homeostasis but decreased plasma insulin level in obese MSG rats. (A) Blood glucose level during the OGTT. (B) Increased percentage of blood glucose at each time point in OGTT. (C) Blood glucose level during the ITT. (D) Decreased percentage of glucose level at each time point in ITT. OGTT was performed in 4 h fasted animals on 6th week of treatment and ITT on 7th week. (E) Plasma superoxide dismutase level, (F) Plasma malondialdehyde level, (G) Plasma nitric oxide level, and (H) Plasma insulin level in obese MSG rats treated with water or fenofibrate. Nor, normal rats. Con, water treated obese MSG rats. Fen, fenofibrate treated obese MSG rats. Values represented means ± s.e.m. (n = 10-12). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.

Back to article page